Collegium Pharmaceutical, Inc. ( COLL ) NASDAQ Global Select

Cena: 39.09 ( -1.09% )

Aktualizacja 08-22 21:58
NASDAQ Global Select
Branża: Drug Manufacturers - Specialty & Generic
Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

Collegium Pharmaceutical, Inc., specjalistyczna firma farmaceutyczna, rozwija i komercjalizuje leki do zarządzania bólem. Jego portfolio obejmuje Xtampza ER, nadużycie, rozszerzone, rozszerzone uwalniane, doustne sformułowanie oksykodonu; NucyntA i NucyntA IR, które są rozszerzonym uwalnianiem i sformułowania tapentadolu w natychmiastowym uwalnianiu; i xtampza er za leczenie bólu wystarczająco ciężkiego, aby wymagać codziennego, całodobowego, długoterminowego leczenia opioidowego. Firma była wcześniej znana jako Collegium Pharmaceuticals, Inc. i zmieniła nazwę na Collegium Pharmaceutical, Inc. w październiku 2003 r. Collegium Pharmaceutical, Inc. został zarejestrowany w 2002 roku i ma siedzibę w Stoughton, Massachusetts.

Informacje o spółce:
Sektor: Zdrowie
Branża: Drug Manufacturers - Specialty & Generic
Zatrudnienie: 197
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 95.7286
Ilość akcji: Brak danych
Debiut giełdowy: 2015-05-07
WWW: https://www.collegiumpharma.com
CEO: Mr. Vikram Karnani
Adres: 100 Technology Center Drive
Siedziba: 02072 Stoughton
ISIN: US19459J1043
Wskaźniki finansowe
Kapitalizacja (USD) 1 231 417 089
Aktywa: 1 635 154 000
Cena: 39.09
Wskaźnik Altman Z-Score: 1.0
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: 36.9
Ilość akcji w obrocie: 96%
Średni wolumen: 322 658
Ilość akcji 31 502 100
Wskaźniki finansowe
Przychody TTM 599 245 000
Zobowiązania: 1 400 875 000
Przedział 52 tyg.: 23.23 - 42.287
Piotroski F-Score: 7
Silny (dobra jakość finansowa)
EPS: 1.1
P/E branży: 22.5
Beta: 0.949
Raport okresowy: 2025-11-06
WWW: https://www.collegiumpharma.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Shirley R. Kuhlmann Executive Vice President, General Counsel, Chief Administrative Officer & Secretary 788 451 1984
Ms. Colleen Tupper Executive Vice President & Chief Financial Officer 782 645 1976
Mr. Scott Dreyer Executive Vice President & Chief Commercial Officer 693 539 1972
Dr. Thomas B. Smith FAAFP, M.D. Executive Vice President & Chief Medical Officer 693 271 1961
Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. Co-Founder, Chairman, Interim Chief Executive Officer & President 110 000 1964
Mr. Scott Sudduth Head of Technical Operations 0 0
Dr. Christopher Shayne James M.D. Vice President of Investor Relations 0 0
Mr. Bart J. Dunn Executive Vice President of Strategy & Corporate Development 0 0
Lista ETF z ekspozycją na akcje Collegium Pharmaceutical, Inc.
Symbol ETF Ilość akcji Wartość
IJR 1 972 273 58 892 086
IWM 793 163 23 683 852
CALF 313 988 9 375 681
IWO 289 441 8 642 694
IJT 289 308 8 638 734
SPSM 278 854 8 581 994
PJP 210 703 6 468 582
PBE 206 569 6 341 668
VTWO 163 212 4 826 178
SLYG 156 580 4 807 790
SCHA 152 106 4 621 154
VIOO 106 432 3 147 194
DFAS 102 905 3 072 743
VHT 99 616 2 945 645
IHE 89 234 2 664 514
SFLO 85 118 2 541 623
DFAC 76 821 2 293 875
XPH 75 608 2 335 715
IWC 75 084 2 242 021
AVSC 66 879 2 053 185
FNDA 51 191 1 552 125
R2SC.L 50 832 1 182 563
R2US.L 50 832 1 560 542
ZPRR.DE 50 832 1 366 566
EES 50 076 1 495 269
IUS3.DE 46 540 1 215 706
IDP6.L 46 540 1 389 696
ISP6.L 46 540 1 051 833
SIXS 43 283 0
ITOT 42 193 1 259 897
FESM 38 658 1 212 314
VIOG 38 280 1 131 939
JPSE 38 233 1 141 637
PRFZ 36 747 1 128 132
SIXL 33 000 0
PSCH 30 817 946 081
VTWG 28 324 837 540
IUSN.DE 28 056 732 856
WSML.L 28 056 837 741
WLDS.L 28 056 634 069
GSSC 27 549 891 485
RWJ 24 102 739 931
RZG 23 425 719 147
AVUS 22 313 685 009
PSC 22 253 664 474
SMMV 20 791 638 283
BTEE.L 19 809 591 496
2B70.DE 19 809 517 441
BTEC.L 19 809 591 496
BTEK.L 19 809 447 692
SCHB 19 395 593 184
XRS2.DE 19 158 500 956
XRSU.L 19 158 572 063
XRSG.L 19 158 43 350 422
JSML 18 547 553 813
ONEQ 17 110 536 569
RSSL 16 334 487 733
DSMC 15 659 467 577
DFUV 15 235 454 917
FHLC 13 603 426 590
IJR.AX 11 342 538 952
IWV 9 249 276 177
SMLV 9 229 286 462
DFAU 7 813 233 296
TILT 7 700 229 922
CAFG 6 516 194 567
ROSC 6 279 192 765
XSU.TO 5 548 235 237
ZPRV.DE 4 726 110 673
USSC.L 4 726 126 383
SXRG.DE 4 058 106 002
CUSS.L 4 058 121 172
CUS1.L 4 058 91 713
CSUSS.MI 4 058 106 002
UWM 3 243 96 835
DCOR 3 030 90 475
D5BM.DE 2 997 78 366
XSXD.L 2 997 89 490
XS5G.L 2 997 67 815
XS5E.DE 2 997 78 366
XSPU.L 2 997 89 490
XSPX.L 2 997 6 781 500
PILL 2 769 82 682
URTY 2 685 80 174
XJR 2 553 78 377
SQLV 2 425 74 447
VTHR 2 413 71 352
SPGM 2 241 68 952
FLQS 1 968 60 417
SPTM 1 870 57 505
AVSU 1 584 48 628
XUU.TO 1 372 58 192
ISCB 1 323 39 510
OMFS 1 249 38 344
BIB 1 185 35 384
DXUV 1 163 34 727
IBBQ 1 137 34 905
XSMC.TO 1 132 47 995
XSMH.TO 1 047 44 395
SAA 593 17 706
FNDB 428 13 052
CBUG.DE 338 8 835
EWSA.AS 338 10 100
VLU 334 10 311
XBAL.TO 237 10 046
XUH.TO 203 6 220
EBIT 174 5 341
MMTM 52 1 592
HDG 39 1 164
DFSU 8 238
XTR.TO 8 251
SC0K.DE 0 79 562
USML.L 0 175 675
PZW.TO 0 5 282
SBIO.L 0 281 301
USFM.L 0 0
RTYS.L 0 90 804
USUE.DE 0 0
SBIO.MI 0 246 476
Wiadomości dla Collegium Pharmaceutical, Inc.
Tytuł Treść Źródło Aktualizacja Link
Collegium Announces $25 Million Accelerated Share Repurchase Program STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program. globenewswire.com 2025-05-12 12:05:00 Czytaj oryginał (ang.)
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Karnani - President and Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Serge Belanger - Needham & Co David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded. seekingalpha.com 2025-05-09 06:04:21 Czytaj oryginał (ang.)
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-05-08 22:31:10 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago. zacks.com 2025-05-08 22:20:47 Czytaj oryginał (ang.)
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. globenewswire.com 2025-05-08 20:01:00 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-05-01 15:08:06 Czytaj oryginał (ang.)
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. globenewswire.com 2025-04-24 12:00:00 Czytaj oryginał (ang.)
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2025-04-23 14:45:49 Czytaj oryginał (ang.)
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. globenewswire.com 2025-04-01 12:00:00 Czytaj oryginał (ang.)
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. globenewswire.com 2025-03-27 10:00:00 Czytaj oryginał (ang.)
Collegium Announces Updates to its Board of Directors and Executive Leadership Team – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman  and Gwen A. Melincoff, Board Member to Retire from Board – globenewswire.com 2025-03-17 09:00:00 Czytaj oryginał (ang.)
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025. globenewswire.com 2025-03-10 20:57:00 Czytaj oryginał (ang.)
Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025 Collegium Pharmaceutical Inc. is a specialty pharma company with strong cash flow, high EBITDA margins, and a focus on non-abusive painkillers and ADHD drugs. The new CEO has a proven track record, previously growing Horizon's revenue from $300 million to $4 billion and selling it to Amgen for $28 billion. The stock is undervalued at 4.5x EBITDA 2024, with potential for re-rating as Jornay PM ramps up and reduces the impact of Nucynta's exclusivity loss. seekingalpha.com 2025-03-09 06:07:46 Czytaj oryginał (ang.)
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in investor meetings at the following investor conferences: Leerink Partners 2025 Global Healthcare Conference Tuesday, March 11, 2025 Jefferies Biotech on the Beach Summit Wednesday, March 12, 2025 Barclays 27 th Annual Global Healthcare Conference Thursday, March 13, 2025 About Collegium Pharmaceutical, Inc. Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. globenewswire.com 2025-03-04 10:00:00 Czytaj oryginał (ang.)
Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Vikram Karnani - President & Chief Executive Officer Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceuticals Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-02-27 23:03:03 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-27 22:00:31 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.58 per share a year ago. zacks.com 2025-02-27 20:45:26 Czytaj oryginał (ang.)
Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million – – Reported Quarterly Jornay PM ® Net Revenue of $29.3 Million and Pro Forma Full-Year Net Revenue of $100.7  Million – – Achieved Quarterly and Full-Year GAAP Net Income of $12.5 Million and $69.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $107.7 Million and $401.2 Million – – Ended 2024 with Cash, Cash Equivalents and Marketable Securities of $162.8 Million; Repurchased $60.0 Million in Shares in 2024 – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. globenewswire.com 2025-02-27 18:01:00 Czytaj oryginał (ang.)
Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Collegium Pharmaceutical (COLL) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com 2025-02-26 12:15:29 Czytaj oryginał (ang.)
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025 STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. globenewswire.com 2025-02-13 10:00:00 Czytaj oryginał (ang.)
Collegium Provides 2025 Financial Guidance and Business Update – Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM ® Net Revenue Expected to be in Excess of $135 Million – – Adjusted EBITDA* Expected in the Range of $435 Million to $450 Million – – Adjusted Operating Expenses* Expected in the Range of $220 Million to $230 Million – STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. globenewswire.com 2025-01-08 10:00:00 Czytaj oryginał (ang.)
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of Jornay PM expands COLL's portfolio into neurology, tapping into the rapidly growing ADHD market, which is projected to reach $30.6 billion by 2032. Collegium reported strong Q3 2024 results, with 17% YoY revenue growth and EBIT margins improving to 35.2%, showcasing operational efficiency. seekingalpha.com 2024-11-26 10:00:00 Czytaj oryginał (ang.)
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD) MONTREAL, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved JORNAY PM™, an extended-release formulation of methylphenidate, a stimulant medication for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children. globenewswire.com 2024-11-14 18:30:00 Czytaj oryginał (ang.)
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-11-13 12:45:42 Czytaj oryginał (ang.)
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock? Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately. zacks.com 2024-11-08 11:35:18 Czytaj oryginał (ang.)
Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interim President and Chief Executive Officer, Founder and Chairman Scott Dreyer - Chief Commercial Officer Colleen Tupper - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities David Amsellem - Piper Sandler Serge Belanger - Needham & Company Oren Livnat - H.C. Wainright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2024 Earnings Conference Call. seekingalpha.com 2024-11-08 02:30:28 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com 2024-11-07 21:30:44 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago. zacks.com 2024-11-07 20:37:37 Czytaj oryginał (ang.)
Collegium Reports Record Third Quarter 2024 Financial Results – Generated Record Q3'24 Net Revenue of $159.3 Million, Up 17% Year-over-Year, Driven by Record Belbuca ® Revenue of $53.2 Million and Record Xtampza ® ER Revenue of $49.5 Million – globenewswire.com 2024-11-07 18:02:00 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-31 13:06:09 Czytaj oryginał (ang.)
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-10-28 12:46:21 Czytaj oryginał (ang.)
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-10-11 14:46:59 Czytaj oryginał (ang.)
Breakouts Boost These Three Stocks To All-Time Highs Three stocks, Blue Owl Capital, Collegium Pharmaceuticals and Armstrong World Industries are at their all time high as they break out from proper bases. investors.com 2024-10-04 18:37:34 Czytaj oryginał (ang.)
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-09-25 14:46:14 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Upgraded to Buy: Here's Why Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2024-09-09 17:00:21 Czytaj oryginał (ang.)
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com 2024-09-09 14:46:36 Czytaj oryginał (ang.)
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. globenewswire.com 2024-08-30 12:00:00 Czytaj oryginał (ang.)
Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Mike Heffernan - Interim President and Chief Executive Officer, Founder & Chairman Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2024-08-09 01:30:09 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-08-08 23:01:18 Czytaj oryginał (ang.)
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.26 per share a year ago. zacks.com 2024-08-08 22:25:31 Czytaj oryginał (ang.)
Collegium Reports Second Quarter 2024 Financial Results – Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca ® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – globenewswire.com 2024-08-08 20:01:00 Czytaj oryginał (ang.)